UNSPSC 51152068: Pipecuronium bromide

This classification denotes a muscle relaxant with the molecular formula C35H62N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6ZTY81RE1, chemically known as 4,4-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1,1-dimethylpiperazinium)dibromide, diacetate (ester) but more generally known as pipecurium bromide, which bears US NIH Compound Identifier 65332. European Medicines Agency schedules Pipecuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14880MIG.

UNSPSC 51152068 Pipecuronium bromide is a Commodity code under which state and local governments procure pharmaceutical products and related medical supplies, though recent activity shows substantial misalignment between the code's nominal scope and actual solicitation content. The code appears in state and local procurement systems primarily through health and human services agencies—county health departments and state health commissions—seeking to acquire naloxone, drug deactivation systems, and direct pharmaceutical distribution capabilities rather than pipecuronium bromide specifically. The work involves competitive bidding for pharmaceutical products to support community health initiatives, with vendors required to meet standard compliance obligations including drug-free workplace certification, E-Verify authorization, and insurance coverage requirements.

Geographic activity centers on Florida and Texas based on recent postings. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, with a response deadline of April 3, 2026. The code shows limited recent activity overall; the mismatch between pipecuronium bromide (a neuromuscular blocking agent) and the naloxone and drug deactivation systems actually being solicited suggests potential misclassification in state procurement systems, warranting verification of accurate code assignment before pursuing opportunities tagged under this designation.